1. Home
  2. CGON

as 05-24-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Founded: 2010 Country:
Canada
Canada
Employees: N/A City: IRVINE
Market Cap: 2.0B IPO Year: 2024
Target Price: $63.75 AVG Volume (30 days): 663.6K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.85 EPS Growth: N/A
52 Week Low/High: $25.77 - $50.23 Next Earning Date: 05-09-2024
Revenue: $539,000 Revenue Growth: N/A
Revenue Growth (this year): 730.39% Revenue Growth (next year): 428.63%

Share on Social Networks:

Stock Insider Trading Activity of CG ONCOLOGY INC (CGON)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Roche Corleen M. CGON CFO & Secretary Jan 29 '24 Buy $19.00 2,000 $38,000.00 2,000 SEC Form 4
Decheng Capital Global Life Sciences Fund IV, L.P. CGON 10% Owner Jan 29 '24 Buy $19.00 400,000 $7,600,000.00 4,958,810 SEC Form 4
Decheng Capital Global Life Sciences Fund IV, L.P. CGON 10% Owner Jan 29 '24 Buy $19.00 400,000 $7,600,000.00 400,000 SEC Form 4
Song Hong Fang CGON Director Jan 29 '24 Buy $19.00 263,157 $4,999,983.00 613,928 SEC Form 4